A World TOP Tier Business Portfolio Focused on Profitability and Capital Efficiency under VISION2030
First written in FY2024. 5 of 9 entries say "Advanced", first in FY2025. Latest entry: 2026-08-06.
The whole theme swung hardest in 2025: 6 of 27 companies on the "Worse" side.
4 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In fiscal 2025, the second year of VISION2030, revenue reached a record high for the fourth consecutive period, operating income for the fifth consecutive period, and net income attributable to owners of the company for the sixth consecutive period. The company is making steady progress toward achieving VISION2030 by allocating funds secured through strengthened business portfolio management and cash flow management to capital investment in growth areas, primarily the biopharmaceutical CDMO and semiconductor materials businesses.」
In the second year of VISION2030, revenue, operating income and net income each reached record highs for the fourth, fifth and sixth consecutive periods, respectively, while funds secured through portfolio and cash management were allocated to the biopharmaceutical CDMO and semiconductor materials businesses. For fiscal 2026, the company expects revenue of ¥3.47 trillion, operating income of ¥365 billion, ROE of 7.8% and ROIC of 5.6%. - FY2026-H1RestatedAnnual report
「There have been no material changes to the management policies, management strategies or other matters established by our Group during the interim consolidated accounting period.」
The company reconfirmed that there were no material changes during the interim consolidated accounting period to its management policies, management strategies or other matters, including VISION2030. - FY2025AdvancedAnnual report
「Fiscal 2024 was the first year of VISION2030, and revenue, operating income and net income attributable to owners of the company each reached a record high for the third consecutive year. The company made a strong start toward achieving VISION2030 by allocating funds secured through strengthened business portfolio management and cash flow management to capital investment in growth areas, primarily the biopharmaceutical CDMO and semiconductor materials businesses.」
In the first year of VISION2030, revenue, operating income and net income reached record highs, while funds secured through portfolio and cash management were allocated to the biopharmaceutical CDMO and semiconductor materials businesses. - FY2025-H1RestatedAnnual report
「There have been no material changes to the management policies, management strategies or other matters established by our Group during the interim consolidated accounting period.」
The company reconfirmed that there were no material changes during the interim consolidated accounting period to its management policies, management strategies or other matters, including VISION2030, introduced in the previous fiscal year. - FY2024First statedAnnual report
「On 17 April 2024, the company announced its new medium-term management plan, "VISION2030." Through management focused on profitability and capital efficiency, VISION2030 aims to enhance the value of the 富士フイルム Group, build an even more resilient business foundation as a portfolio of global top-tier businesses, change the world one step at a time, and create value and smiles for its diverse stakeholders.」
The company presented its first new medium-term management plan following VISION2023, stating its aim to become a portfolio of global top-tier businesses with a focus on profitability and capital efficiency. Its targets for fiscal 2026 are revenue of ¥3.45 trillion, operating income of ¥360 billion, net income attributable to owners of the company of ¥270 billion, ROE of 8.1% and ROIC of 5.8%.